• Now Accepting LOIs for the MM Research Network!

    Community hospitals are invited to advance real-world multiple myeloma research by joining the Network.

    Read More
    News & Events

  • Living with Sickle Cell Disease: New Data Hub Report

    Explore real-world insights from 13,000+ people with SCD in the SCD Data Hub, shaped with guidance from our Community Advisory Board.

    Download the Report
    ASH RC Sickle Cell Disease Data Hub Report 2025 (Banner - Blue)

  • Smarter Insights. Better Care. Real-World Impact for Sickle Cell Disease

    Explore how the ASH RC Data Hub is transforming hematology research with curated real-world data, driving innovation in sickle cell disease and beyond.

    Read Article
    Slider Image 7

  • Access Resources for Clinical Trial Participants

    By participating in a clinical trial for sickle cell disease (SCD), you could help researchers learn more about the disease and create new treatments that can improve the lives of people with SCD.

    Additional Resources
    Slider Image 9

  • ASH Research Collaborative’s Real-World Evidence Consortium for SCD Goes Live with Duke Clinical Research Institute

    The Real-World Evidence Consortium aims to develop consensus recommendations on clinical outcomes to improve care for individuals living with sickle cell disease.

    Read Article
    Slideshow Real World Evidence Consortium

  • Real-World Evidence Initiative Reports Now Available

    The Real-World Evidence Initiative is excited to share the final recommendations from the Genomic Therapies and the Coordinated Registry Network Work Groups. The reports chart out a future path for regulatory science and for genomic therapies.

    Final Recommendations
    Slider Image 1

  • Connect With Us on Social Media

    Follow us on Twitter/X and Facebook as we share the latest updates from ASH RC and connect with those who are also working to improve the lives of people affected by blood diseases.

    Facebook Twitter/X
    Slider Image 8
PreviousNext
1234567
  • Image

Improving Research to Build a Brighter Future for People with Hematologic Conditions

Individuals living with hematologic conditions need more evidence-based options for managing their health and improving their quality of life. The ASH Research Collaborative® (ASH RC) is working to accelerate change by making it more efficient to conduct research, from increasing access to high-quality clinical data to making it easier for individuals with hematologic conditions to participate in studies.

The ASH RC is currently focused in two disease areas: One classical hematologic condition, sickle cell disease (SCD), and one malignant hematologic disease, multiple myeloma (MM).

  • At the heart of both programs are site-based Research Networks consisting of experts in their respective fields.
  • The SCD Research Network fosters collaborative partnerships to accelerate progress in clinical research and improve outcomes for individuals living with SCD by expediting the development of therapeutics and generating high-quality evidence to support clinical decision-making. Learn about the SCD Research Network.
  • The MM Research Network is committed to building relationships within the myeloma community, leveraging the power of real-world evidence, and prioritizing research to improve the lives of individuals living with multiple myeloma. Learn about the MM Research Network.

Both Networks are powered by real-world data (RWD) which we call The Data Hub. The Data Hub is designed to be the largest shared information resource with real-world data to serve the hematology community. Access to these data can accelerate research and development, support regulatory decision-making, and help clinics identify opportunities for quality improvement. Learn about the Data Hub

ASH RC Home

Latest Announcements

News & Events

Multiple Myeloma Investigator Initiated Research

Automated Approach Uses ASH RC Data to Classify Sickle Cell Disease by Similar Genotype

A new study based on multi-site data from the ASH Research Collaborative (ASH RC) Data Hub showcases an automated approach to subclassifying similar genotypes of sickle cell disease using data from electronic health records.
Read more
Disease Modifying Therapies (DMTs)

Real-World Analysis of Voxelotor Outcomes Finds No Clear Sign of Harm, But No Real Benefits

New data finds that the sickle cell drug voxelotor was not associated with any clear indicator of harm to patients, but had limited benefits overall. The findings were based on data pulled from the ASH Research Collaborative (ASH RC) Data Hub.
Read more
Multiple Myeloma Research

Using Conventional Definitions, Some High-Risk Multiple Myeloma Patients May Be Missed

Research using data from the ASH Research Collaborative (ASH RC) Data Hub aims to define “functional high-risk” multiple myeloma, suggesting that newly diagnosed patients whose disease progresses within 30 months of a triplet or quadruplet drug regimen have poorer outcomes than those who progress after 30 months.
Read more
AI Predicts Kidney Disease

Artificial Intelligence Accurately Predicts Chronic Kidney Disease in Individuals with Sickle Cell Disease

New research showcases a first-of-its-kind artificial intelligence algorithm to examine the dynamics underlying chronic kidney disease in individuals living with sickle cell disease. The algorithm employed data from the ASH Research Collaborative (ASH RC) Data Hub.
Read more
Research & Analytics

Clinical Trial Literacy Gaps Exist Among Lived Experience Experts

The ASH Research Collaborative (ASH RC) conducted research among individuals involved in its national and local sickle cell disease community advisory boards (CABs) to assess clinical trial literacy, and found that even among engaged advocates, there were knowledge gaps about clinical trials.
Read more
Multiple Myeloma Research

ASH Research Collaborative Multiple Myeloma Data Hub Award

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Multiple Myeloma Investigator Initiated Research

Iron Overload Remains Prevalent in Individuals with Sickle Cell Disease Despite Diagnosis and Treatment Guidelines

New research presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, finds that iron overload is a prevalent problem for individuals receiving blood transfusions to treat their sickle cell disease.
Read more
Real-World Evidence Consortium for Sickle Cell Disease

Study Finds Potential Protective Uric Acid Range in Individuals with Sickle Cell Disease

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Multiple Myeloma Research

Novel Technique Preserves Patient Privacy and Data Integrity Across Sickle Cell Disease Registries

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
PreviousNext
123456789

Follow Us On Twitter/X

@ASHCOLLAB